$ICLR

Murray Ciaran sold $440K of ICLR

Murray Ciaran sold 2,677 shares of ICON PLC (ICLR) at an average of $164.29 ($162.72–$165.51, $0.44M total) across 4 trades on 2026-08-11.

Original reporting
SEC EDGAR · Murray Ciaran
Published Aug 12, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 9:13 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ICLR
Neutral
medium confidence
Mentioned
$ICLR
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ICLRNeutralLow
01

Why it matters

Traders may briefly reassess sentiment around insider behavior, but the disclosure lacks any new operational, financial, or regulatory information.

02

Market read

A director’s open-market sale is disclosed, which can slightly pressure sentiment but is usually not a standalone trading catalyst.

03

What to watch

No 10b5-1 plan is cited, but the article does not provide context on total holdings, compensation timing, or whether other insiders sold/bought around the same period.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-12, covering sales executed 2026-08-11

Background

The article is a Form 4 insider transaction disclosure for ICON PLC, reporting director Murray Ciaran’s open-market sale.

Company-level read

Ticker impact

$ICLRNeutralMedium confidence
Context

ICON PLC director Murray Ciaran sold about $439.8K of ICLR shares via an open-market sale across four trades on 2026-08-11.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and typically fades as Form 4 sales are common.

Evidence & confidence

The filing provides transaction size, dates, and price range, but no accompanying company-specific news, guidance, or legal/regulatory catalyst.

Market effects

No clear sector read-through; this is an issuer-specific insider transaction.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification, taxes, or pre-planned liquidity needs, especially given the multi-trade execution over a narrow price band.

Key entities

  • ICON PLC

    The company whose director insider sale is disclosed on Form 4.

  • Murray Ciaran

    Director who sold 2,677 shares of ICON PLC for about $439,803.17.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ICLRMedAI 9/10

ICON plc: ICON Reports Second Quarter 2026 Results

ICON plc (NASDAQ: ICLR) reported Q2 2026 results. Revenue was $2,063.5 million, up 1.4% QoQ. Adjusted EBITDA was $327.2 million (15.9% of revenue). GAAP net income was $72.6 million ($0.94 diluted EPS) and adjusted net income was $198.4 million ($2.56 adjusted EPS). Net business wins were $3,120 million, backlog $23.4 billion, and it reaffirmed 2026 guidance.

$ICLRHighAI 8/10

ICON PLC (ICLR): Financial results for Q2 2026

ICON PLC (ICLR) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 ICON Reports Second Quarter 2026 Results Highlights • Quarter two revenue of $2,063.5 million, an increase of 1.4% on quarter one 2026. • Quarter two adjusted EBITDA of $327.2 million or 15.9% of revenue, an increase of 3.0% on quarter one 2026. • GAAP net income for

$ICLRMed

ICON stock surges 7% on Anthropic AI partnership for trials By Investing.com

ICON plc (NASDAQ:ICLR) shares rose about 7.8% after the company announced a multi-year partnership with Anthropic to integrate Claude AI into its Orbis clinical trial platform. ICON said the collaboration will add four production capabilities, including site intelligence and enrollment risk detection, and will roll out Claude across roles. ICON cited enrollment delays affecting up to 80% of trials.

$ICLRMed

ICON, Anthropic Sign Multi-Year Partnership Deal To Advance AI Capabilities, Stock Up In Pre-Market

ICON Public Limited Company (ICLR) said it signed a multi-year partnership with Anthropic to integrate Claude AI across the clinical trial lifecycle using ICON’s Orbis platform. ICON plans to work with Anthropic’s life sciences team and deploy Claude Code, Claude, and Claude Science. The company cited CEO Barry Balfe. In pre-market, ICLR rose to $177.69, up 5.28% on Nasdaq.